Myriad Validates Polygenic Score to Predict Breast Cancer Risk
Myriad Genetics (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced results from an important study to validate the polygenic component of a forthcoming riskScore test for Hispanic women who test negative for a hereditary cancer mutation with the myRisk Hereditary Cancer test. As quoted in the press release: “A year ago, we launched riskScore … Continued
Myriad Genetics (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced results from an important study to validate the polygenic component of a forthcoming riskScore test for Hispanic women who test negative for a hereditary cancer mutation with the myRisk Hereditary Cancer test.
As quoted in the press release:
“A year ago, we launched riskScore as a significant enhancement to myRisk® to provide women of European ancestry with additional genetic information about their lifetime risk of developing breast cancer,” said Jerry Lanchbury, Ph.D., chief scientific officer, Myriad Genetics. “This year we are excited to presents results from almost 14,000 women which is the largest polygenic study ever conducted for Hispanic ancestry. It is another step in our commitment to make riskScore accessible to all women, including those most underrepresented in our health care system.”
The key data being presented at SABCS are summarized below. Please visit Myriad at Booth #1001 to learn more about genetic testing for breast cancer. Follow Myriad on Twitter via @myriadgenetics and keep up to date with Symposium news and updates by using the hashtag #SABCS18.
Click here to read the full press release.
